BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 19159435)

  • 1. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
    Ren H; Tan X; Dong Y; Giese A; Chou TC; Rainov N; Yang B
    Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):241-52. PubMed ID: 19159435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
    Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
    Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate).
    Mukherjee J; Kamnasaran D; Balasubramaniam A; Radovanovic I; Zadeh G; Kiehl TR; Guha A
    Cancer Res; 2009 Jun; 69(12):5099-107. PubMed ID: 19509233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.
    Weigel MT; Meinhold-Heerlein I; Bauerschlag DO; Schem C; Bauer M; Jonat W; Maass N; Mundhenke C
    Cancer Lett; 2009 Jan; 273(1):70-9. PubMed ID: 18809244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptotic effect of imatinib on human colon adenocarcinoma cells: influence on actin cytoskeleton organization and cell migration.
    Popow-Woźniak A; Woźniakowska A; Kaczmarek L; Malicka-Błaszkiewicz M; Nowak D
    Eur J Pharmacol; 2011 Sep; 667(1-3):66-73. PubMed ID: 21658383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Imatinib induces c-kit positive myeloma cells apoptosis].
    Li J; Huang BH; Zhao Y; Luo SK
    Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):230-3. PubMed ID: 18843975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the histone deacetylase inhibitor valproic acid on the sensitivity of anaplastic thyroid cancer cell lines to imatinib.
    Catalano MG; Pugliese M; Poli R; Bosco O; Bertieri R; Fortunati N; Boccuzzi G
    Oncol Rep; 2009 Feb; 21(2):515-21. PubMed ID: 19148530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
    Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
    Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib targeting of KIT-mutant oncoprotein in melanoma.
    Jiang X; Zhou J; Yuen NK; Corless CL; Heinrich MC; Fletcher JA; Demetri GD; Widlund HR; Fisher DE; Hodi FS
    Clin Cancer Res; 2008 Dec; 14(23):7726-32. PubMed ID: 19047099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate inhibits proliferation and exerts an antifibrotic effect in human breast stroma fibroblasts.
    Gioni V; Karampinas T; Voutsinas G; Roussidis AE; Papadopoulos S; Karamanos NK; Kletsas D
    Mol Cancer Res; 2008 May; 6(5):706-14. PubMed ID: 18505916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/ß expression in squamous cell carcinoma of the head and neck in vitro.
    Schultz JD; Rotunno S; Riedel F; Anders C; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
    Int J Oncol; 2011 Apr; 38(4):1001-12. PubMed ID: 21249316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of sodium butyrate on proliferation of human gastric cancer cells and expression of p16 gene].
    Shen WJ; Dai DQ; Teng Y; Liu J
    Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(17):1192-6. PubMed ID: 18844115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
    Bright SA; Greene LM; Greene TF; Campiani G; Butini S; Brindisi M; Lawler M; Meegan MJ; Williams DC; Zisterer DM
    Biochem Pharmacol; 2009 Feb; 77(3):310-21. PubMed ID: 19014913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrphostin AG1478 suppresses proliferation and invasion of human breast cancer cells.
    Zhang YG; Du Q; Fang WG; Jin ML; Tian XX
    Int J Oncol; 2008 Sep; 33(3):595-602. PubMed ID: 18695891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer.
    Bran B; Bran G; Hörmann K; Riedel F
    Int J Oncol; 2009 Jan; 34(1):255-61. PubMed ID: 19082496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local delivery of poly lactic-co-glycolic acid microspheres containing imatinib mesylate inhibits intracranial xenograft glioma growth.
    Benny O; Menon LG; Ariel G; Goren E; Kim SK; Stewman C; Black PM; Carroll RS; Machluf M
    Clin Cancer Res; 2009 Feb; 15(4):1222-31. PubMed ID: 19190128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SC68896, a novel small molecule proteasome inhibitor, exerts antiglioma activity in vitro and in vivo.
    Roth P; Kissel M; Herrmann C; Eisele G; Leban J; Weller M; Schmidt F
    Clin Cancer Res; 2009 Nov; 15(21):6609-18. PubMed ID: 19825946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.
    Knight B; Tirnitz-Parker JE; Olynyk JK
    Gastroenterology; 2008 Sep; 135(3):969-79, 979.e1. PubMed ID: 18602920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.